A closer examination revealed that CEA-derived MAPs (for example, those derived from CEACAM5 or CEACAM7) were excluded from our analysis following the initial peptide classification, which removes MAPs that are not overexpressed at least 10-fold higher in cancer than in matched NAT, and those that are expressed more than 2 RPHM in NAT. This evidence concerns the gene CEACAM5 and cancer.